EUCAST Guidance Documents

Now in reverse chronological order.....

• When there are no breakpoints (30 June, 2023), Previous version (1 December 2021 - 30 June, 2023), Previous version (5 July, 2016 - 1 December 2021). 
• ATU - the Area of Technical Uncertainty - Guidance to laboratories on how to deal with the ATU in antimicrobial susceptibility testing (21 Dec, 2018; update 2 Jan, 2019, update 1 June, 2020, update 15 January, 2022).
  Graphs to illustrate ATUs (Update 20 Febr, 2023).
• Guidance on the use of ceftriaxone and cefotaxime in Staphylococcus aureus (8 February, 2023)
• Aminopenicillin breakpoints Enterobacterales following revision 2023 - guidance on implementation (14 January, 2023; an error in the flowchart was corrected on Sept 15, 2023).
• Setting breakpoints for agent-inhibitor combinations (14 December, 2021). Previous version of Setting breakpoints for agent-inhibitor combinations (2 October, 2017).
• Breakpoints in brackets in breakpoint tables (2 December 2021)
• Phenotypic screening tests to detect and exclude resistance of clinical relevance (update 22 August, 2022). Previous version (13 June, 2022). Previous version (2 Febr, 2022). Previous version (1 Dec 2021)
• Implementation and use of the 2022 revised colistin breakpoints (January, 2022; minor edits on previous version from Nov, 2021)
• Legionella pneumophila susceptibility testing (30 May, 2021); previous version Legionella pneumophila susceptibility testing (11 Dec, 2017) 
• Cefiderocol MIC broth microdilution (17 December, 2020). See also the Warning on cefiderocol susceptibility testing.
• Implementation and use of the 2020 revised aminoglycoside breakpoints (first published 21 Jan, 2020; updated April 2020) 
• Daptomycin in endocarditis and bloodstream infections caused by enterococci (also available in CMI as a EUCAST position paper; 2020)
• Breakpoints for topical use of antimicrobial agents (revised 12 April 2022, 21 Nov, 2019; 22 Dec, 2016) 
• Guidance for industry on the working order between pharmaceutical industry, EMA and EUCAST (5 May, 2019)
• Cefotaxime and ceftazidime disks with and without clavulanic acid for ESBL confirmation (12 February, 2019)
• Guidance on tigecycline dosing, 21 July, 2022. Previous version (23 December, 2018)
• The 2019 modifications of susceptibility categories S, I and R categories (22 October, 2018).
  This presentation also informs laboratories on how to implement the Area of Technical Uncertainty.
• EUCAST system for antimicrobial name abbreviations (January 2022). Previous version (13 July, 2018) 
• Recommendations for colistin (polymyxin E) MIC testing - joint EUCAST and CLSI recommendation (22 March, 2016)
• Burkholderia cepacia complex (20 July, 2013)
• Stenotrophomonas maltophilia (1 Feb 2012)
• Oral cephalosporins and Enterobacterales breakpoints (14 July, 2020). Previous version (16 Feb 2012)
• Direct susceptibility testing (16 Feb 2012)

Aminopen